13/06/2019 - 12:38

MGC cranks up medical cannabis orders

13/06/2019 - 12:38

Bookmark

Upgrade your subscription to use this feature.

MGC Pharmaceuticals has received a 50% increase in medical cannabis product orders from Australian distributors Health House International and Cannvalate due to both repeat and new prescriptions. The company also expects to conclude the Phase II clinical trial for its CogniCann medical cannabis treatment for dementia and Alzheimer’s patients about 12 months ahead of schedule thanks to the high level of interest.

Subscribe today for award-winning, unbiased and trusted journalism

Subscription Options